Home Cart Sign in  
Chemical Structure| 566205-01-4 Chemical Structure| 566205-01-4

Structure of 566205-01-4

Chemical Structure| 566205-01-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 566205-01-4 ]

CAS No. :566205-01-4
Formula : C4H2Br2ClN3
M.W : 287.34
SMILES Code : BrC1=NC(=C(N=C1N)Cl)Br
MDL No. :MFCD11043607
InChI Key :KMOICDJWYSOXRT-UHFFFAOYSA-N
Pubchem ID :45789662

Safety of [ 566205-01-4 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 566205-01-4 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 46.85
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

51.8 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.77
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.45
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.25
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.39
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.0

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.61
Solubility 0.0707 mg/ml ; 0.000246 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.18
Solubility 0.189 mg/ml ; 0.000659 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.61
Solubility 0.0707 mg/ml ; 0.000246 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.31 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.55

Application In Synthesis of [ 566205-01-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 566205-01-4 ]

[ 566205-01-4 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 33332-28-4 ]
  • [ 566205-01-4 ]
YieldReaction ConditionsOperation in experiment
94.7% With N-Bromosuccinimide; In water; acetonitrile; at 0 - 20℃; for 18h; Synthesis Example 12-Amino-3,5-dibromo-6-chloropyrazine (4)To a solution of <strong>[33332-28-4]2-amino-6-chloropyrazine</strong> (3) (8.00 g, 61.8 mmol) in acetonitrile (80 mL) was gradually added N-bromosuccinimide (NBS) (27.5 g, 155 mmol) at 0° C.After elevating to room temperature, the mixture was stirred overnight (18 hours).To the mixture was added water and the product was extracted with diethyl ether (*3).The combined organic extract was washed successively with water (*1) and brine (*1), followed by drying over anhydrous sodium sulfate.After filtration and concentration under reduced pressure, the residue was purified by silica gel flash column chromatography (n-hexane/ethyl acetate=3/1) to give 2-amino-3,5-dibromo-6-chloropyrazine (4) (16.8 g, 58.5 mmol, 94.7percent) as a yellow solid. TLC Rf=0.31 (n-hexane/ethyl acetate=4/1); 1H NMR (500 MHz, CDCl3) delta 5.14 (s, 2H); 13C NMR (126 MHz, CDCl3) delta 120.7, 122.0, 146.1, 151.0.
94.7% With N-Bromosuccinimide; In acetonitrile; at 0 - 20℃; for 18h; N-bromosuccinimide(NBS) (27.5 g, 155 mmol) was slowly added, was warmed up to room temperatureovernight (18 hours) and the mixture was stirred. Water was added thereto andthe product was extracted with ethyl acetate (× 3). The organic layer waswashed with water (× 1) and saturated brine (× 1), and dried over anhydroussodium sulfate. After filtration, the filtrate was concentrated under reducedpressure, and the residue was purified by silica gel flash columnchromatography (n- hexane / ethyl acetate = 3/1),2-amino-3,5-dibromo-6-chloropyrazine (4) (16.8 g , 58.5 mmol, 94.7percent) as ayellow solid
82% With N-Bromosuccinimide; In methanol; at 20℃; for 0.5h;Inert atmosphere; <strong>[33332-28-4]2-Amino-6-chloropyrazin</strong>e (0.6 g, 4.63 mmol) was dissolved in MeOH (50 mL), and N-bromosuccinimide (1.81 g, 10.19 mmol) was added to the solution with stirring. The mixture was stirred at room temperature for 30 min. The reaction mixture was concentrated, ethyl acetate was added and washed with water. The organic layer was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to give 2-amino-3,5-dibromo-6-chloropyrazine 1c (1.09 g, 82percent) as a slightly yellow solid. 1H NMR (400 MHz, CDCl3) delta5.26 (br, 2H).
70% With N-Bromosuccinimide; In acetonitrile; at 0 - 20℃; To a solution of <strong>[33332-28-4]2-amino-6-chloropyrazine</strong> (1 g, 7.72 mmol) in anhydrous acetonitrile (10 mL) was gradually added NBS (4.12 g, 23.16 mmol, 3 equiv.) at 0°C. The reaction mixture was slowly warmed up to r.t. and stirred overnight then diluted with water and extracted with Et20. Combined organic layers were washed with water and brine, then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified byflash chromatography on silica eluting with Hexane/EtOAc (1:1)to give the title compound (1.55 g, 5.39 mmol, 70percent) as a pale yellow solid. ESI-MS: 287.90 [M+H]+.
38% With N-Bromosuccinimide; In chloroform; at 20℃; for 5h;Inert atmosphere; To a solution of 6-chloro-pyrazin-2-ylamine (5.0 g, 38.8 mmol) in chloroform (194 mL) was added N-bromosuccinimide (20.7 g, 116 mmol) under a nitrogen atmosphere and the reaction mixture was stirred at room temperature for 5 h. The resulting mixture was poured into an aqueous solution of K2CO3 (300 mL) and extracted with dichloromethane (200 mL x 4). The combined organic extracts were dried and purified by chromatography (silica, 10-20 percent ethyl acetate in hexanes) to give 3,5-dibromo-6-chloro-pyrazin-2-ylamine (4.2 g, 38percent) as a yellow solid. LC-MS: 286.0 (M-H).
With N-Bromosuccinimide; In chloroform; for 20h;Reflux; A solution of 6-chloropyrazin-2-amine (2 g, 15.44 mmol) and N BS (13.7 g, 77 mmol) in CHCI3 (100 ml) was heated at reflux for 20 hours. The resulting mixture was purified bychromatography on silica eluting with DCM. The relevant fractions were concentrated in vacuo and the crude product was dissolved in EtOAc (~100 ml), washed with 10 percent sodium thiosulfate (2 x 100 ml), brine, dried (MgS04) and were concentrated in vacuo to afford the title compound; 1 H NMR (400 MHz, CDCI3) delta 5.4-5.0 (2H, br s).
With N-Bromosuccinimide; In methanol; at 15 - 20℃; for 2h;Cooling with ice; 6-Chloropyrazin-2-amine (100 g, 772 mmol) in MeOH (2000 ml) cooled using a water bath was treated with N-bromosuccinimide (151.2 g, 170 mmol) portionwise over 30 mins, maintaining the reaction temperature between 15-20° C. After stirring for 1.5 hours, the mixture was poured carefully into a stirred vessel of ice-cooled water (4 litres). The resultant suspension was stirred for 2 hours in the ice bath, collected by filtration, rinsing the filter cake with water (800 ml) and dried in a vacuum oven to afford the titled compound; LC-MS Rt 0.99 mins; Method 2 minLowpH
With N-Bromosuccinimide; In chloroform; for 20h;Heating / reflux; A stirred solution of <strong>[33332-28-4]2-amino-6-chloropyrazine</strong> (2.0g) and JV-bromosuccinimide (13.71g) inchloroform (100 mL) was heated to reflux for 20 hours. The reaction mixture was cooledand concentrated onto silica gel (20g) and the residue loaded onto a column of silica gel(5cm x 2cm) and the column was eluted with dichloromethane. Concentration afforded3,5-dibromo-<strong>[33332-28-4]6-chloro-2-aminopyrazine</strong> that was dissolved into methanol (200 mL) andsodium methoxide (32g of a 25percent solution in methanol) added. The reaction was heated to70°C for 1.5h, cooled and concentrated to approx. 50 mL capacity. The reaction mixturewas poured into water (200mL) and the sub-titled adduct (2.0g) collected as an off-whitesolid.m/e 235, 237 (M+l+, 100percent)

 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 566205-01-4 ]

Bromides

Chemical Structure| 173253-42-4

A900854 [173253-42-4]

2-Amino-5-bromo-6-chloropyrazine

Similarity: 0.84

Chemical Structure| 212779-21-0

A121865 [212779-21-0]

2-Amino-3-bromo-6-chloropyrazine

Similarity: 0.83

Chemical Structure| 76537-18-3

A334911 [76537-18-3]

3-Bromo-5-chloropyrazin-2-amine

Similarity: 0.83

Chemical Structure| 24241-18-7

A844496 [24241-18-7]

2-Amino-3,5-dibromopyrazine

Similarity: 0.79

Chemical Structure| 957230-70-5

A140286 [957230-70-5]

3,6-Dibromopyrazin-2-amine

Similarity: 0.76

Chlorides

Chemical Structure| 173253-42-4

A900854 [173253-42-4]

2-Amino-5-bromo-6-chloropyrazine

Similarity: 0.84

Chemical Structure| 212779-21-0

A121865 [212779-21-0]

2-Amino-3-bromo-6-chloropyrazine

Similarity: 0.83

Chemical Structure| 76537-18-3

A334911 [76537-18-3]

3-Bromo-5-chloropyrazin-2-amine

Similarity: 0.83

Chemical Structure| 912773-21-8

A225706 [912773-21-8]

2-Bromo-5-chloropyrazine

Similarity: 0.66

Chemical Structure| 33332-29-5

A207833 [33332-29-5]

2-Amino-5-chloropyrazine

Similarity: 0.62

Amines

Chemical Structure| 173253-42-4

A900854 [173253-42-4]

2-Amino-5-bromo-6-chloropyrazine

Similarity: 0.84

Chemical Structure| 212779-21-0

A121865 [212779-21-0]

2-Amino-3-bromo-6-chloropyrazine

Similarity: 0.83

Chemical Structure| 76537-18-3

A334911 [76537-18-3]

3-Bromo-5-chloropyrazin-2-amine

Similarity: 0.83

Chemical Structure| 24241-18-7

A844496 [24241-18-7]

2-Amino-3,5-dibromopyrazine

Similarity: 0.79

Chemical Structure| 957230-70-5

A140286 [957230-70-5]

3,6-Dibromopyrazin-2-amine

Similarity: 0.76

Related Parent Nucleus of
[ 566205-01-4 ]

Pyrazines

Chemical Structure| 173253-42-4

A900854 [173253-42-4]

2-Amino-5-bromo-6-chloropyrazine

Similarity: 0.84

Chemical Structure| 212779-21-0

A121865 [212779-21-0]

2-Amino-3-bromo-6-chloropyrazine

Similarity: 0.83

Chemical Structure| 76537-18-3

A334911 [76537-18-3]

3-Bromo-5-chloropyrazin-2-amine

Similarity: 0.83

Chemical Structure| 24241-18-7

A844496 [24241-18-7]

2-Amino-3,5-dibromopyrazine

Similarity: 0.79

Chemical Structure| 957230-70-5

A140286 [957230-70-5]

3,6-Dibromopyrazin-2-amine

Similarity: 0.76